{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:27:09Z","timestamp":1788798429780,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SFRH\/BD\/43399\/2008"],"award-info":[{"award-number":["SFRH\/BD\/43399\/2008"]}]},{"name":"FCT\u2014Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["SFRH\/BPD\/66288\/2009"],"award-info":[{"award-number":["SFRH\/BPD\/66288\/2009"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.urolonc.2013.05.009","type":"journal-article","created":{"date-parts":[[2013,8,12]],"date-time":"2013-08-12T22:45:43Z","timestamp":1376347543000},"page":"44.e1-44.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["FASL polymorphism is associated with response to bacillus Calmette-Gu\u00e9rin immunotherapy in bladder cancer"],"prefix":"10.1016","volume":"32","author":[{"given":"Lu\u00eds","family":"Lima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Morais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A.","family":"Videira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00facio","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2013.05.009_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/978-0-387-89520-8_5","article-title":"The role of FasL and Fas in health and disease","volume":"647","author":"Ehrenschwender","year":"2009","journal-title":"Adv Exp Med Biol"},{"issue":"6513","key":"10.1016\/j.urolonc.2013.05.009_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/373444a0","article-title":"Fas(CD95)\/FasL interactions required for programmed cell death after T-cell activation","volume":"373","author":"Ju","year":"1995","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.urolonc.2013.05.009_bib3","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.4049\/jimmunol.166.10.6074","article-title":"CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ","volume":"166","author":"Radoja","year":"2001","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.urolonc.2013.05.009_bib4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0002-9440(10)63910-7","article-title":"Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression","volume":"162","author":"Chopin","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.urolonc.2013.05.009_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.coph.2004.03.008","article-title":"The Fas signalling pathway and its role in the pathogenesis of cancer","volume":"4","author":"Houston","year":"2004","journal-title":"Curr Opin Pharmacol"},{"issue":"8\u20139","key":"10.1016\/j.urolonc.2013.05.009_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0161-5890(97)00081-3","article-title":"Identification and characterization of polymorphisms in the promoter region of the human Apo-1\/Fas (CD95) gene","volume":"34","author":"Huang","year":"1997","journal-title":"Mol Immunol"},{"issue":"1","key":"10.1016\/j.urolonc.2013.05.009_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4049\/jimmunol.170.1.132","article-title":"A novel polymorphic CAAT\/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients","volume":"170","author":"Wu","year":"2003","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.urolonc.2013.05.009_bib8","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/ejhg.2009.45","article-title":"The FAS ligand promoter polymorphism, rs763110 (\u2212844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies","volume":"17","author":"Zhang","year":"2009","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.urolonc.2013.05.009_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/carcin\/bgp016","article-title":"FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies","volume":"30","author":"Zhang","year":"2009","journal-title":"Carcinogenesis"},{"issue":"4","key":"10.1016\/j.urolonc.2013.05.009_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.fpc.0000194425.58511.a7","article-title":"Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis","volume":"16","author":"Li","year":"2006","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"10.1016\/j.urolonc.2013.05.009_bib11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2013.05.009_bib12","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2013.05.009_bib13","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2217\/imt.10.32","article-title":"Recent advances in bacillus Calmette-Guerin immunotherapy in bladder cancer","volume":"2","author":"Alexandroff","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.urolonc.2013.05.009_bib14","doi-asserted-by":"crossref","first-page":"232609","DOI":"10.1155\/2012\/232609","article-title":"Predictive biomarkers of bacillus calmette-guerin immunotherapy response in bladder cancer: where are we now?","volume":"2012","author":"Lima","year":"2012","journal-title":"Adv Urol"},{"issue":"12","key":"10.1016\/j.urolonc.2013.05.009_bib15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00432-011-1056-3","article-title":"BCG response prediction with cytokine gene variants and bladder cancer: where we are?","volume":"137","author":"Ahirwar","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2013.05.009_bib16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2013.05.009_bib17","first-page":"3729","article-title":"Perforin-mediated lysis of tumor cells by Mycobacterium bovis bacillus Calmette-Guerin-activated killer cells","volume":"6","author":"Brandau","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.urolonc.2013.05.009_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1189\/jlb.1211623","article-title":"Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-alpha but not through TRAIL and FasL","volume":"92","author":"Jinesh","year":"2012","journal-title":"J Leukoc Biol"},{"issue":"4","key":"10.1016\/j.urolonc.2013.05.009_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1159\/000331882","article-title":"IL-4 and TNF-alpha polymorphisms are associated with risk of multiple superficial tumors or carcinoma in situ development","volume":"87","author":"Lima","year":"2011","journal-title":"Urol Int"},{"issue":"1","key":"10.1016\/j.urolonc.2013.05.009_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/sj.pcan.4501002","article-title":"Association between FAS polymorphism and prostate cancer development","volume":"11","author":"Lima","year":"2008","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"Suppl. 3","key":"10.1016\/j.urolonc.2013.05.009_bib21","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1086\/314066","article-title":"Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms","volume":"31","author":"Prescott","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.urolonc.2013.05.009_bib22","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.urology.2009.02.053","article-title":"Efficacy of bacille Calmette-Guerin immunotherapy predicted by expression of antigen-presenting molecules and chemokines","volume":"74","author":"Videira","year":"2009","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.urolonc.2013.05.009_bib23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000085934","article-title":"Fas ligand and TNF-related apoptosis-inducing ligand induction on infiltrating lymphocytes in bladder carcinoma by bacillus Calmette-Guerin treatment","volume":"75","author":"Mehmut","year":"2005","journal-title":"Urol Int"},{"issue":"7","key":"10.1016\/j.urolonc.2013.05.009_bib24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.20050707","article-title":"FASL-844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer","volume":"202","author":"Sun","year":"2005","journal-title":"J Exp Med"},{"issue":"3","key":"10.1016\/j.urolonc.2013.05.009_bib25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00418-008-0479-7","article-title":"RNA expression analysis from formalin fixed paraffin embedded tissues","volume":"130","author":"Farragher","year":"2008","journal-title":"Histochem Cell Biol"},{"issue":"4","key":"10.1016\/j.urolonc.2013.05.009_bib26","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s11255-011-9948-3","article-title":"Utilizing mRNA extracted from small, archival formalin-fixed paraffin-embedded prostate samples for translational research: assessment of the effect of increasing sample age and storage temperature","volume":"43","author":"Stewart","year":"2011","journal-title":"Int Urol Nephrol"},{"issue":"7","key":"10.1016\/j.urolonc.2013.05.009_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1089\/dna.2009.0982","article-title":"Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population","volume":"29","author":"Gangwar","year":"2010","journal-title":"DNA Cell Biol"},{"issue":"4","key":"10.1016\/j.urolonc.2013.05.009_bib28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2013.05.009_bib29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3109\/01913123.2012.681833","article-title":"Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin immunotherapy","volume":"36","author":"Ajili","year":"2012","journal-title":"Ultrastruct Pathol"},{"issue":"7","key":"10.1016\/j.urolonc.2013.05.009_bib30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143913002093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143913002093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:08:34Z","timestamp":1761041314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143913002093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1078143913002093"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.05.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FASL polymorphism is associated with response to bacillus Calmette-Gu\u00e9rin immunotherapy in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2013.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}